|
Osteotech,
Inc. is a global leader in the processing of human bone and
connective tissue for transplantation and an innovator in
the development, manufacturing and marketing of biologic,
biomaterial and device systems for musculoskeletal surgery.
With a particular focus on spinal, trauma, and total joint
revision procedures, the Company's current and development-stage
technologies address needs within numerous musculoskeletal
disciplines.
Our strategy leverages our core competency in biological sciences,
to fulfill unmet clinical needs of the worldwide orthopaedic
surgical community. As a technology leader in orthobiologics,
we focus on creating and redefining select orthopaedic market
segments through the application of innovative regeneration
technologies. Additionally, we have business alliances and
product development initiative that are aimed at providing
a broad base of unique non-biologic technologies that work
in concert with our biologically active tissue forms. The
combination of these technology platforms, coupled with our
distribution network, offer the potential for consistent revenue
and pre-tax profit growth.
Since
its formation in 1986, the Company has become the world's
largest processor of aseptic allograft bone tissue yielding
over 4.5 million grafts. Used in spinal fusions,
to replace cancerous tissue, fill voids caused by trauma,
augment prostheses and replace damaged ligaments and tendons,
bone tissues processed by Osteotech improve the quality of
life for more than 500 transplant recipients every day. In addition, the Company has acquired 90% of OST Developpement in France, which will enable the Company to
expand its allograft business throughout Western Europe.
Osteotech continues to develop a series of human tissue technologies
for use in musculoskeletal surgery. The first such technology,
Grafton® Demineralized Bone
Matrix (DBM) Gel, was introduced in mid-1991. Grafton
Gel is demineralized allograft bone that is processed into
a proprietary gel-like consistency and provided in sterile
single-patient delivery containers.
Grafton® DBM Flex, a proprietary pliable form of DBM,
was introduced in January 1996; Grafton®
DBM Putty, a moldable, putty-like form of DBM, was introduced
in November 1996. Two new forms, Grafton®
DBM Crunch for graft site support and Grafton®
DBM Matrix PLF, for posterolateral spine fusions, have
also recently been added to the Grafton® DBM line. These
new forms. like Flex and Putty, are made from bone fibers,
not particles. Osteotech is the only company to produce DBM
from bone fibers. All Grafton® DBM forms help form bone
through osteoconduction and osteoinduction and are processed
in a manner that has been scientifically validated to be a
viral inactivation process. To date, the Company's Grafton®
DBM forms have been used in over 400,000 surgical procedures
by more than 4,000 transplant professionals, worldwide.
In 2000, the Company developed and launched four new Graftech®
structural allograft systems, which incorporate Osteotech's
proprietary processing technologies. Osteotech entered the
rapidly expanding cervical market with two unique grafts,
Graftech® Cervical Spacer
and Graftech® Cervical Dowel,
both processed from select dense, cancellous tissue. In addition,
the Company's lumbar offerings include the Graftech®
Posterior Ramp and Graftech®
Anterior Ramp, featuring OsteoActive® surfaces demonstrated
to promote bone formation. The Company continues to develop
new technologies to benefit patients as well as maximize the
gift of donation.
A
public company since 1991, Osteotech maintains its executive
offices at 51 James Way, Eatontown, New Jersey, 07724, U.S.A.,
telephone (732) 542-2800.
|
